Jan-Nygaard Jensen, global head of computational biology and digital science at Boehringer Ingelheim GmbH, says the German pharma is focused on a longer-term view to use artificial intelligence and big data applications to de-risk drug development so that it is less resource-intensive and time-consuming.
After a bit more than 18 months at BI heading up its digital science efforts – which include recent partnerships with Google and Yale University – Jensen says the company is not
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?